Erythropoietin in cancer: a dilemma in risk therapy
2013 (English)In: Trends in endocrinology and metabolism, ISSN 1043-2760, E-ISSN 1879-3061, Vol. 24, no 4, 190-199 p.Article, review/survey (Refereed) Published
Erythropoietin (EPO) is a frequently prescribed drug for treatment of cancer-related and chemotherapy-induced anemia in cancer patients. Paradoxically, recent preclinical and clinical studies indicate that EPO could potentially accelerate tumor growth and jeopardize survival in cancer patients. In this review I critically discuss the current knowledge and broad biological functions of EPO in association with tumor growth, invasion, and angiogenesis. The emphasis is focused on discussing the complex interplay between EPO and other tumor-derived factors in angiogenesis, tumor growth, invasion, and metastasis. Understanding the multifarious functions of EPO and its reciprocal relation with other signaling pathways is crucial for developing more effective agents for cancer therapy and for minimizing risks for cancer patients.
Place, publisher, year, edition, pages
Elsevier , 2013. Vol. 24, no 4, 190-199 p.
angiogenesis, cancer therapy, erythropoietin, erythropoiesis, anemia
Engineering and Technology
IdentifiersURN: urn:nbn:se:liu:diva-103401DOI: 10.1016/j.tem.2012.10.007ISI: 000317948300004OAI: oai:DiVA.org:liu-103401DiVA: diva2:689075
Funding Agencies|Swedish Research Council||Swedish Cancer Foundation||Karolinska Institute Foundation||Karolinska Institute||Tianjin Natural Science Foundation (CMM-Tianjin)|09ZCZDSF04400|Torsten Soderbergs foundation||European Union Integrated Project of Metoxia|222741|European Research Council (ERC) advanced grant ANGIOFAT|250021|2014-01-202014-01-202014-01-20